# PLB-015

Source: https://onco.cc/drugs/plb-015/  
OnCo record `plb-015` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

PLB-015 is an experimental dual-payload antibody-drug conjugate from PrimeLink BioTherapeutics, in preclinical development for HER2-positive solid tumours.

## Summary

PLB-015 is a dual-payload antibody-drug conjugate from PrimeLink BioTherapeutics. An anti-HER2 ADC carrying two payloads, a TOP1 inhibitor and an ATR inhibitor, designed to overcome resistance to TOP1 inhibitors. Its furthest stage is preclinical development, for HER2-positive solid tumours. No clinical trial naming it is registered on ClinicalTrials.gov. Preclinical poster at AACR 2026 (company release 2026-04-13). It has not been shown to work in people.

## Fields

- Kind: Treatment
- Status: preclinical
- Last checked: 2026-11-03
- Tags: pipeline
- Code: PLB-015
- Modality: Dual-payload antibody-drug conjugate
- Mechanism: An anti-HER2 ADC carrying two payloads, a TOP1 inhibitor and an ATR inhibitor, designed to overcome resistance to TOP1 inhibitors.

## Sources

- PrimeLink BioTherapeutics: en.primelinkbio.com: http://en.primelinkbio.com/news_detail/16.html

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- targets: [HER2](https://onco.cc/targets/her2/)
- companies: [PrimeLink BioTherapeutics](https://onco.cc/companies/primelink-biotherapeutics/)

---
JSON: https://onco.cc/api/v1/entities/plb-015.json